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Abstract
Background: Previous studies showed that cyclooxygenase(COX) was involved in ischemia/reperfusion (I/R) injuries.
Parecoxib, a selective inhibitor for COX −2, has been shown to have protective properties in reducing I/R injury in
the heart, kidney and brain. The aim of this study was to investigate the effects of parecoxib on hepatic I/R and to
explore the underlying mechanisms.
Methods: Fifty-two Sprague–Dawley rats were randomly divided into three groups: the sham-operation (Sham)
group, the hepatic ischemia/reperfusion (I/R) group, and the parecoxib pretreated I/R (I/R + Pare) group. Partial
warm ischemia was produced in the left and middle hepatic lobes of Sprague–Dawley rats for 60 min, followed by
6 h of reperfusion. Rats in the I/R + Pare group received parecoxib (10 mg/kg) intraperitoneally twice a day for three
consecutive days prior to ischemia. Blood and tissue samples from the groups were collected 6 h after reperfusion,
and a survival study was performed.
Results: Pretreatment with parecoxib prior to I/R insult significantly reduced I/R-induced elevations of aminotransferases,
and significantly improved the histological status of the liver. Parecoxib significantly suppressed inflammatory cascades,
as demonstrated by attenuations in TNF-α and IL-6. Parecoxib significantly inhibited iNOS and nitrotyrosine expression
after I/R and significantly attenuated I/R-induced apoptosis. The 7-day survival rate was increased by pre-administration
of parecoxib.
Conclusions: Administration of parecoxib prior to hepatic I/R attenuates hepatic injury through inhibition of
inflammatory response and nitrosative stress.
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Background
Hepatic ischemia/reperfusion (I/R) is an important fac-
tor for the morbidity associated with several clinical
conditions and interventions including orthotopic liver
transplantation, hepatectomy, and shock. In these condi-
tions, reperfusion induces further hepatocellular damage
due to the accumulation of inflammatory cells and medi-
ators, reactive oxygen species, and the subsequent bio-
chemical derangements in intracellular homeostasis [1].
Hepatic I/R injury may lead to delayed graft function
and a higher incidence of chronic rejections in the case
of transplant recipients, or increase the complications
and length of hospital stay for patients experiencing
hepatectomy or shock [2].
Hepatic injuries induced by I/R are the result of
complex interactions between various inflammatory
mediators, among which, cyclooxygenase (COX)-derived
prostanoids such as prostacyclin (PGI) and prostaglandin
E (PGE) have been shown to play a critical role [3, 4].
COX is an enzyme that catalyzes the oxygenation of
arachidonic acid to prostaglandin endoperoxides, which
are converted into prostaglandins subsequently. There
are at least two cyclooxygenase isoenzymes, COX-1 and
COX-2. COX-1 is constitutively expressed in most cells
and contributes to the synthesis of prostanoids, while
COX-2 is undetectable in most cells in normal condition
but is rapidly induced in pathological conditions, par-
ticularly in the immune system [5, 6]. Previous studies
have shown that both COX-1 and COX-2 are involved
in skeletal muscle and gastric I/R injuries [7, 8]. Inhib-
ition of COX-2 by gene knock-out was found to cause a
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significant reduction in I/R-induced hepatic damage [9].
However, the mechanisms under the protective effect
are yet to be well investigated. Thus we used pare-
coxib, a selective COX-2 inhibitor, which has been
widely used to relieve perioperative pain, and has
been indicated to have protective properties in redu-
cing I/R injury in the heart, kidney and brain [10–12], to




This study was approved by the Animal Care Committee
of the First Affiliated Hospital of Sun Yat-sen University,
Guangzhou, China, and was performed in accordance
with the committee’s guidelines for use of experimental
animals. Fifty-two adult specific pathogen-free male
Sprague–Dawley rats weighing between 250 and 300 g
were obtained from the Animal Center of Sun Yat-sen
University, Guangzhou, China. Animals were housed in
individual cages in a temperature-controlled room with
12 h light–dark cycles. Food was removed 8 h before the
surgery, although all animals had free access to water.
The rats were randomly divided into three groups: the
sham-operation (Sham) group, the hepatic ischemia/
reperfusion (I/R) group, and the parecoxib pretreated
I/R (I/R + Pare) group.
Drug preparation and treatment schedule
Parecoxib (Pfizer, USA) was diluted in isotonic saline.
The parecoxib treatment group was injected with pare-
coxib (10 mg/kg) intraperitoneally twice a day for three
consecutive days prior to ischemia. The rats in sham
and I/R groups were injected intraperitoneally with the
same volume of isotonic saline at the same time. The
parecoxib dosage was determined based on previous
studies [11, 12].
Animal model of hepatic I/R
On the day of surgery, 1 h after the last injection of par-
ecoxib or saline, all animals were anesthetized with
pentobarbital (40 mg/kg, intraperitoneal). A 3-cm
midline incision was performed and the hilum of the
liver was exposed. All structures in the portal triad
(hepatic artery, portal vein and bile duct) to the left
and median liver lobes were occluded by a clip in
order to produce 70 % hepatic ischemia. The clip
was removed after 60 min, and the abdomen closed.
Sham-operated animals underwent midline laparot-
omy only, without hepatic ischemia. Core body
temperature was maintained between 35.5-36.5 °C
with the aid of a heating pad. Blood and liver sam-
ples of 6 rats of each group were collected 6 h after
reperfusion and stored at −80 °C prior to use. The
remaining rats in the I/R group and the I/R + Pare
group (n = 16-18/group) were monitored for 7 days to
record survival.
Evaluation of liver injury
Blood samples were centrifuged at 4,000 rpm for 12 min
to collect serum, which was then stored at −80 °C before
use. Serum levels for alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) were determined
by a serum autoanalyzer (H-7600; Hitachi Ltd., Tokyo,
Japan). Liver tissue were taken from the median lobe 6 h
after reperfusion and stored in 10 % formalin before be-
ing fixed in paraffin. Biopsies were then sectioned and
stained with hematoxylin-eosin. Liver histologic injury
was assessed using a semi-quantitative light microscopy
evaluation. The histologic injury score for each sample
was expressed as the sum of the individual scores for 6
different parameters: cytoplasmic color fading, vacuoli-
zation, nuclear condensation, nuclear fragmentation,
nuclear fading, and erythrocyte stasis [13]. Scores for each
finding ranged from 0 (0 %), to 1 (1-10 %), 2 (10-50 %), or
3 (>50 %). Each sample score was averaged over 10 micro-
scopic fields.
Survival study
For the survival study, the non-ischematized 30 % of the
liver was resected at the onset of reperfusion. The ani-
mals in the I/R group and the I/R + Pare group were
monitored for 7 days to record survival.
Determination of TNF-α and IL-6 levels in the liver
and serum
Total RNA was isolated from the liver tissue samples
using the Trizol reagent (Invitrogen, Carlsbad, CA, USA)
as described in the manufacturer's instructions. Quanti-
tative PCR was performed using a Light-Cycler® 480
Real-Time PCR System (Roche, Basel, Switzerland) and
the SYBR Green qPCR Master Mix (2X) (Fermentas,
USA). The primer sequences: TNF-α: Forward: 5’-
GTCTGTGCCTCAGCCTCTTC-3’; Reverse: 5’-CCCA
TTTGGGAACTTCTCCT-3’. IL-6: Forward: 5’-GCCC
TTCAGGAACAGCTATG-3’; Reverse: 5’-GTCTCCTC
TCCGGACTTGTG-3’. Each expression gene was nor-
malized with GAPDH mRNA using a Delta-Delta CT
method. The gene activity in the shame group was
assigned as 1 as a reference. Serum TNFα and IL-6
levels were determined using an ELISA kit (Biosource
International, camarillo, CA, USA).
Hepatic myeloperoxidase measurement
100 mg liver tissue was homogenized in 1 ml of KPO4
buffer containing 0.5 % hexadecyltrimethyl-ammonium
bromide by sonication and cultivated at 60 °C for 2 h.
Samples were centrifuged to collect the supernatant, and
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then measured for protein concentration in a 96-well
plate by adding samples into phosphate buffer contain-
ing o-dianisidine hydrochloride and H2O2. Light absorb-
ance was read at 460 nm over a period of 5 minutes.
MPO activity (1 unit was equal to the change in ab-
sorbance per min) was expressed as units per gram of
tissue.
TUNEL staining
Fluorescence staining was conducted using a commer-
cially available In Situ Cell Death Detection Kit (Roche).
The assay was performed according to the manufacturer’s
instructions. The nucleus was stained with propidium iod-
ide. Results were expressed as the average number of
TUNEL positive cells per 10 microscopic fields.
Fig. 1 Effect of parecoxib on hepatocyte injury after hepatic I/R. Serum samples were collected 6 h after reperfusion from the sham, I/R,
and I/R + Pare groups for measuring AST a and ALT b. Data presented as means ± SE (n = 6/group) and compared by one-way ANOVA and
SNK method. *P < 0.05 vs. I/R group
Fig. 2 Effect of parecoxib on tissue damage and cellular architecture in the liver after hepatic I/R. Histological findings of the liver were exhibited
in the sham a, I/R b, and I/R + Pare c groups. Liver tissues were stained with hematoxylin-eosin. Representative photomicrographs at
200× magnification. d Semi-quantitative histologic injury score. Data presented as means ± SE (n = 6/group) and compared by one-way
ANOVA and SNK method. *P < 0.05 vs. I/R group
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Measurement of iNOS and nitrotyrosine
Liver tissue samples were homogenized in lysis buffer
(Promega, Madison, WI, USA) for protein extraction.
The homogenates were centrifuged at 850× g for
10 min to collect supernatants, and then centrifuged
at 10,000× g for an additional 10 min. The superna-
tants were isolated for western blot analysis. Protein
concentration was determined using the BCA protein
assay (Pierce, Rockford, IL, USA). Equal amounts of
protein were separated on an SDS polyacrylamide gel,
and then transferred onto a nitrocellulose membrane
(Millipore, Temecula, CA, USA). Membranes were in-
cubated with primary antibodies against iNOS (1:500;
Santa Cruz Biotechnology, Santa Cruz, CA) or nitro-
tyrosine, a marker for peroxynitrite (ONOO−) (1:500;
Upstate Cell Signaling Solutions, Lake Placid, NY).
All protein bands were detected by species specific in-
frared fluorescent secondary antibodies (Cell Signaling
Technology, Danvers, MA, USA). The relative amount of
each protein was normalized by the ratio to GAPDH and
analyzed using Image J (free software from the National
Institutes of Health, USA).
Statistical analysis
SPSS 16.0 was used for the statistical analysis. All
data are expressed as a mean ± SE and compared by
one-way analysis of variance (ANOVA) and the Student-
Newman-Keuls (SNK) test. Survival rates were ana-
lyzed by the Kaplan-Meier method using a log-rank
test. P <0.05 in two-tailed testing was considered to
be statistically significant.
Results
Parecoxib alleviated liver tissue injury after hepatic I/R
Hepatocyte damage was assessed by measuring serum
AST and ALT levels, which increased by 46- and 28-
fold, respectively, 6 h after hepatic I/R compared with
the Sham group (Fig. 1). Contrastingly, treatment with
parecoxib prior to I/R significantly reduced injury levels
by 43 % and 48 %, respectively as compared to the
Fig. 3 The effect of parecoxib on the proinflammatory cytokine expression and neutrophil infiltration into the liver after hepatic I/R. Liver tissues
were harvested 6 h after reperfusion from the sham, I/R, and I/R + Pare groups. TNF-α a and IL-6 b mRNA expression in the liver were measured
by quantitative RT-PCR analysis. Serum TNFα c and IL-6 d levels were determined using an ELISA kit. Liver tissue myeloperoxidase (MPO) activity e, a
marker for neutrophil infiltration, was determined spectrophotometrically. Data presented as means ± SE (n = 6/ group) and compared by one-way
ANOVA and SNK method. *P < 0.05 vs. I/R group
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control I/R group (Fig. 1). This data correlated with the
alterations in tissue histological change. As compared to
the sham group (Fig. 2a), livers in the I/R group showed
marked coagulation necrosis, severe architerctural ab-
normalities and nuclear condensation (Fig. 2b), which
was dramatically reduced in parecoxib-treated rats
(Fig. 2c). As shown in Fig. 2d, animals undergoing I/R
with control treatment exhibited a significant increase of
liver histologic injury score as comapared to sham-
operated animals, which was reduced by 64 % with ad-
ministration of parecoxib.
Parecoxib reduced the inflammatory cytokines in the liver
after hepatic I/R
TNF-α and IL-6 levels in the liver and change of hepatic
neutrophil infiltration were measured to ascertain the
inflammatory responses after hepatic I/R. At 6 h after
reperfusion, hepatic I/R resulted in a 15-fold increase of
TNF-α and 18-fold increase of IL-6 mRNA expression
in comparison to sham, which was decreased by 46 %
and 65 % when parecoxib was administered (Fig. 3a
and b). Serum TNF-α and IL-6 levels were also de-
creased by administration of parecoxib compared to IR
group (Fig. 3c and d). When compared to the sham group,
control-treated animals showed a 5-fold increase in
hepatic tissue levels of MPO, which was not reduced sig-
nificantly by administration of parecoxib (Fig. 3e).
Parecoxib reduced I/R-induced apoptosis
The result of TUNEL staining showed that parecoxib
decreased the frequency of apoptotic TUNEL positive
cells in livers compared with IR group (Fig. 4).
Parecoxib lowered nitrosative stress after hepatic I/R
In order to determine the effect of parecoxib on nitrosa-
tive burden following I/R, hepatic tissue levels of iNOS
and nitrotyrosine were evaulated. Compared with the
sham group, we observed a significant increase in iNOS
and nitrotyrosine protein expression in the control I/R
group, which was reduced by administration of pare-
coxib (Fig. 5).
Parecoxib improved survival after hepatic I/R
Only 22.2 % of I/R animals survived 7 days after hepatic
I/R. Contrastingly, parecoxib significantly improved sur-
vival rate to 56.2 % after hepatic I/R (Fig. 6) (P = 0.04).
Discussion
Research aimed at the prevention and treatment of
hepatic I/R has gained great attention because of the
Fig. 4 Effect of parecoxib on apoptosis in the liver after hepatic I/R. a TUNEL-staining 6 hours after reperfusion. b Results scored semi-quantitatively by
averaging the number of apoptotic cells per field at 200 ×magnification (n = 6 /group). Data presented as means ± SE and compared by one-way
ANOVA and SNK method. *P < 0.05 vs. I/R group
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growing number of orthotopic liver transplantation,
hepatectomy and other critical patients. In this study, we
evaluated the protective effect of parecoxib on hepatic
I/R injury. ALT and AST levels in the parecoxib-
pretreated group were significantly lower compared to
the control I/R group. Histological damage was milder in
the parecoxib group than in the control group. Parecoxib
pre-administration also reduced I/R-induced apoptosis
and improved survival rate after hepatic I/R. Thus, the
administration of parecoxib before ischemia appears to
protect rats against hepatic I/R injury.
Ischemia reperfusion is a common pathophysiological
process, which can induce altered COX-1/COX-2 ex-
pression in various organs such as in the muscle and
liver [7, 14]. Studies also have shown that both COX-1
and COX-2 contribute to I/R-induced hepatic micro-
vascular and hepatocellular injury in hepatic I/R injury
[9, 15]. A nonselective COX-1/ COX-2 inhibitor, Flurbi-
profen, has been shown to be protective in hepatic I/R
injury [16]. In this study, we firstly elucidated the pro-
tective effect of parecoxib, a widely used selective COX-2
inhibitor during the perioperative period, on hepatic I/R
injury. This further demonstrated the important role of
COX in hepatic I/R injury.
Inflammatory cascades play an important role in the
tissue damage during I/R. COX-2 is a major inflamma-
tory mediator [17, 18]. Buvanendran et al. has shown
that rofecoxib, a COX-2 inhibitor, is potent inhibitors of
IL-6 expression through reduced prostaglandin produc-
tion [19]. Feng et al. also has shown that administration
of rofecoxib decreased blood levels of TNF-α and IL-6
in patients after total knee replacement [20]. TNF-α, one
of the main mediators of hepatic I/R injury, is known to
have deleterious effects on the hepatocytes [21]. Hyper-
stimulation of IL-6 has been suggested to inhibit liver re-
generation [22]. Hepatic ischemia/reperfusion results in
an enhanced spontaneous release of these inflammatory
Fig. 6 Effect of pre-administration of parecoxib on survival after
hepatic I/R. Survival rates over a 7-day period following 70 % hepatic
I/R were demonstrated for the I/R group (n = 18) and the I/R + Pare
group (n = 16). Survival rates were analyzed by the Kaplan-Meier
method using a log-rank test. *P < 0.05 vs. I/R group
Fig. 5 Effect of parecoxib administration on iNOS and nitrotyrosine expression in liver homogenates. a Western blot results for iNOS and
nitrotyrosine. b Relative amount for iNOS and nitrotyrosine. Data presented as means ± SE (n = 4/ group) and compared by one-way
ANOVA and SNK method. *P < 0.05 vs. I/R group
Zhang et al. BMC Anesthesiology  (2015) 15:165 Page 6 of 8
cytokines by Kupffer cells early after reperfusion [23].
Our study showed that parecoxib administration signifi-
cantly inhibited the production of inflammatory cyto-
kines after hepatic I/R, which may contribute to its
preventive effect on the liver after I/R, although it did
not reduced the level of MPO in liver tissue.
Nitrosative stress also has been recognized to contrib-
ute to the cellular damage associated with I/R injury
[24]. When iNOS is upregulated in I/R injury the exces-
sive nitric oxide (NO) produced will react with super-
oxide anion (O2 −), creating peroxynitrite (ONOO−).
Peroxynitrite then aggravates the injury through lipid
peroxidation, apoptosis, and necrosis by nitration of
tyrosine residues on tissue proteins [25]. It has been re-
vealed that iNOS specifically binds to COX-2 and that
NOS inhibition decreases prostaglandin formation [18].
Nitrotyrosine, a marker for peroxynitrite (ONOO−), and
iNOS are often used as markers of nitrosative stress.
In the present study, we observed that parecoxib ad-
ministration lead to decreased iNOS and nitrotyrosine
levels in hepatic I/R, which suggested that parecoxib
decreased the nitrosative stress caused by I/R. This
result is consistent with the decrease in number of
apoptotic cells.
Conclusion
In summary, the study showed that pretreatment of par-
ecoxib reduced I/R-induced liver injury, inflammatory
response, and nitrosative stress, and improved survival
rate after hepatic I/R. These results provides evidence
that parecoxib, an analgesic widely used perioperatively,
could be a protective pharmacological strategy to pre-
vent hepatic I/R injury.
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